Logotype for SELLAS Life Sciences Group Inc

SELLAS Life Sciences Group (SLS) Corporate presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for SELLAS Life Sciences Group Inc

Corporate presentation summary

20 Nov, 2026

GPS clinical results and development

  • REGAL met its primary OS endpoint in transplant-ineligible AML in CR2 or later: 41% lower risk of death; median OS 24.0 vs 14.7 months, HR 0.59, p=0.035.

  • The randomized global Phase 3 trial enrolled 126 patients; GPS was generally well tolerated, with mostly Grade 1/2 treatment-related AEs and no new safety signals.

  • FDA discussions and preparations for an expedited BLA are planned; GPS also has potential label expansion after CR1 and post-transplant.

  • GPS is an engineered, multivalent WT1-targeting immunotherapy; WT1 is expressed in ~97% of AML, with potential application across 20+ hematologic and solid cancers.

SLS009 clinical progress

  • Completed Phase 2 study met all primary endpoints; at the optimal 30 mg BIW dose, ORR was 40% and median OS was 8.8 months in r/r AML after venetoclax-based therapy.

  • In adverse-risk subsets, monocytic AML had 54% ORR and 5.8-month median OS; TP53-mutated AML had 57% ORR and 8.8-month median OS.

  • No dose-limiting toxicities or treatment-related high-grade toxicities were observed; hematologic toxicity was consistent with aza/ven alone.

  • The 80-patient frontline AML Phase 2 trial has enrolled 40; cohorts target patients predicted not to benefit from aza/ven or with confirmed early nonresponse, with preliminary data expected Q4 2026.

SLS009 mechanism and research

  • SLS009 is a selective CDK9 inhibitor designed to suppress CDK9 by ~99.7%; CDK9 inhibition may reduce MCL-1 and c-MYC, promoting apoptosis and cell-cycle arrest.

  • In a daraxonrasib-resistant pancreatic cancer model, SLS009 induced 17.9% apoptosis and 14.5% necrosis, versus 2.8% and 2.7% with daraxonrasib.

  • The NIH-funded PIVOT program evaluates SLS009 in pediatric tumors; in 27 patient-derived ALL models, median survival approximately tripled versus vehicle and 25/27 models showed delayed progression.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from SELLAS Life Sciences Group